Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) EBT Margin (2022 - 2025)

Oramed Pharmaceuticals' EBT Margin history spans 4 years, with the latest figure at 352.9% for Q1 2025.

  • For Q1 2025, EBT Margin fell 9378.0% year-over-year to 352.9%; the TTM value through Dec 2025 reached 7349.4%, changed N/A, while the annual FY2025 figure was 3766.2%, 189985.0% up from the prior year.
  • EBT Margin reached 352.9% in Q1 2025 per ORMP's latest filing, up from 4152.49% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 194.81% in Q2 2023 to a low of 4152.49% in Q2 2024.
  • Average EBT Margin over 4 years is 1281.02%, with a median of 1048.83% recorded in 2022.
  • Peak YoY movement for EBT Margin: soared 149911bps in 2023, then crashed -395768bps in 2024.
  • A 4-year view of EBT Margin shows it stood at 1355.64% in 2022, then skyrocketed by 86bps to 194.81% in 2023, then tumbled by -2032bps to 4152.49% in 2024, then skyrocketed by 92bps to 352.9% in 2025.
  • Per Business Quant, the three most recent readings for ORMP's EBT Margin are 352.9% (Q1 2025), 4152.49% (Q2 2024), and 259.12% (Q1 2024).